BiotechTube

Experimental: stage I：HSK21542 0.4 μg/kg + Experimental: stage I：HSK21542 1 μg/kg + Experimental: stage I：HSK21542 0.5μg/kg + Experimental: stage I：HSK21542 1μg/kg + Experimental: stage II：HSK21542 0.5μg/kg + Experimental: stage II：HSK21542 1μg/kg + Placebo

Phase 2Completed
0 watching 0 views this week⚡ Active
49
Hype Score

Development Stage

✓
Pre-clinical
✓
Phase 1
3
Phase 2
4
Phase 3
5
Approved
Indication / Disease

Analgesia

Conditions

Analgesia

Trial Timeline

Jul 2, 2020 → Jan 5, 2021

NCT ID
NCT04424251

About Experimental: stage I：HSK21542 0.4 μg/kg + Experimental: stage I：HSK21542 1 μg/kg + Experimental: stage I：HSK21542 0.5μg/kg + Experimental: stage I：HSK21542 1μg/kg + Experimental: stage II：HSK21542 0.5μg/kg + Experimental: stage II：HSK21542 1μg/kg + Placebo

Experimental: stage I：HSK21542 0.4 μg/kg + Experimental: stage I：HSK21542 1 μg/kg + Experimental: stage I：HSK21542 0.5μg/kg + Experimental: stage I：HSK21542 1μg/kg + Experimental: stage II：HSK21542 0.5μg/kg + Experimental: stage II：HSK21542 1μg/kg + Placebo is a phase 2 stage product being developed by Haisco Pharmaceutical Group for Analgesia. The current trial status is completed. This product is registered under clinical trial identifier NCT04424251. Target conditions include Analgesia.

Hype Score Breakdown

Clinical
17
Activity
12
Company
7
Novelty
5
Community
5

Clinical Trials (1)

NCT IDPhaseStatus
NCT04424251Phase 2Completed

Competing Products

20 competing products in Analgesia

See all competitors
ProductCompanyStageHype Score
AcetaminophenJohnson & JohnsonPhase 2
52
HRF2105 patch + Loxoprofen patch + placeboJiangsu Hengrui MedicinePhase 2
52
Bupivacaine Liposome Injection T preparation + Bupivacaine Liposome Injection R preparationJiangsu Hengrui MedicinePhase 1
33
Bupivacaine Liposome InjectionJiangsu Hengrui MedicineApproved
85
Paracetamol injection + Normal Saline injection + Morhpine PCAJiangsu Hengrui MedicinePhase 2/3
65
Bupivacaine Liposome Injection + Bupivacaine Hydrochloride InjectionJiangsu Hengrui MedicinePhase 2
52
Org 28611 + morphine sulfate + PlaceboMerckPhase 2
52
oxycodone hydrochloride + oxycodone hydrochloride + oxycodone hydrochloride + oxycodone hydrochloride + marketed oxycodone hydrochloridePfizerPhase 1
32
Ibuprofen 600 mg Immediate Release/Extended Release CapletPfizerPhase 3
76
HSK21542 Injection + Tramadol hydrochloride + placeboHaisco Pharmaceutical GroupPhase 3
74
Stage I: HSK21542 0.5 μg/kg + Stage I: HSK21542 1 μg/kg + HSK21542 0.5 μg/kg + HSK21542 1 μg/kg + HSK21542 2 μg/kg + PlaceboHaisco Pharmaceutical GroupPhase 2
49
HSK21542 + PlaceboHaisco Pharmaceutical GroupPhase 3
74
HTX-011 + Ibuprofen + Acetaminophen + Celecoxib + +/- Bupivacaine HCl + HTX-011Heron TherapeuticsPhase 3
69
HTX-011 + Bupivacaine Hydrochloride + Ibuprofen + AcetaminophenHeron TherapeuticsApproved
77
HTX-011 + HTX-011 + Ibuprofen + AcetaminophenHeron TherapeuticsPhase 2
44
Bupivacaine HClHeron TherapeuticsApproved
77
HTX-011 + PlaceboHeron TherapeuticsPhase 2
44
HTX-011 + Ibuprofen + AcetaminophenHeron TherapeuticsPhase 3
69
Bupivacaine liposome injectable suspension + Bupivacaine HCl without epinephrine via continuous infusionHeron TherapeuticsApproved
77
HTX-011 + Bupivacaine HCl + HTX-011 + HTX-011 + HTX-011Heron TherapeuticsPhase 2
44

Other Products from Haisco Pharmaceutical Group

Crisugabalin + PlaceboApproved
82
Polyene phosphatidylcholine injection 930 mg QD + Magnesium Isoglycyrrhizinate injection 200 mg QDApproved
82
Cyclopofol + PropofolApproved
82
Ciprofol + PropofolApproved
82
CipepofolApproved
82